glp-1 gip weight loss treatments comparison I compare two medications with my patients every single week. Here's what the data actually shows. Semaglutide (Ozempic/Wegovy) delivered a 13.7% average weight loss in clinical trials. That's significant. But This will blow your mind🤯

Always consult a qualified healthcare provider before starting, stopping, or changing any medication or supplement regimen

Biometals 25 , 677686 (2012)

Retatrutide : Currently in Phase 3 trials, this triple agonist (GLP-1, GIP, and glucagon receptors) has shown 24.2% average weight loss in a Phase 2 study

Additionally, granulosa cells in women with endometriosis exhibit apoptosis, mitochondrial dysfunction, disrupted steroid hormone production, and increased inflammatory markers, further compromising follicle health ( These changes contribute to significant oocyte quality defects

Findings were generally similar across the weighted and propensity-score-matched analyses